Autoimmune diseases are pathologies caused by a loss of immune tolerance to multiple autoantigens, targeting specific cell types, tissues or organs, or by a systemic immune response. For most autoimmune diseases, induction of autoantigen-specific regulatory T cells has become the therapeutic option of choice. Many studies have shown that pMHC-based nanomedicines can induce and amplify disease-suppressing regulatory T cells and are capable of fully suppressing organ-specific autoimmunity without compromising normal immunity.

As an expert in the field of MHC, Creative BioMart can provide pMHC-NPs new therapeutic development services, offering solutions for the development of nanoparticles coated with pMHC to induce regulatory T cells in vivo, which can treat a variety of autoimmune diseases such as type 1 diabetes, multiple sclerosis, and allergies.

pMHC-NPs Promote T Regulatory Cells in Immune Diseases

pMHC-NPs can promote the formation and expansion of antigen-specific Treg cells and suppress many autoimmune responses. In such nanoparticles, pMHC represents specific antigens that are attached to nanoparticles composed of iron oxide nanoparticles via PEG joints, which can send profound and sustained signals to homologous T cells. It promotes the differentiation of pre-activated auto-reactive CD4+ T cells into TR1-like cells and their systemic expansion, which then suppress auto-reactive helper and cytotoxic T cells by secreting IL-10, TGFβ, etc., thus resolving complex autoimmune diseases.

Fig.1 Induction of antigen-specific Treg cells by pMHC-NPs (Yang Y and Pere S, 2022)

Our Services

• pMHC-NPs Development for Type 1 Diabetes. Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by the immune system attacking pancreatic islet cells. Nanoparticles coated with pMHC can induce antigen-specific regulatory T cells in vivo, thereby suppressing T1D disease without affecting general immunity. We provide solutions for the development of NPs carrying diabetes-related peptide-MHC-like complexes, advancing the development of specific therapeutic approaches against T1D and thus preventing and treating diabetes.
• pMHC-NPs Development for Liver Autoimmune Pathologies. Liver autoimmune disease is an organ-specific autoimmune disease in which the autoimmune response is focused on non-organ-specific antigens enriched in the liver. pMHC-NPs are able to exhibit antigens associated with but commonly expressed in liver autoimmune diseases, attenuating various liver autoimmune diseases in a non-disease-specific manner without suppressing local or systemic immunity to infectious agents or cancer.
• pMHC-NPs Development for Multiple Sclerosis. Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that causes an autoimmune response in the CNS through infection and environmental factors, and there is still a lack of effective treatments. We can provide immunotherapy services to develop specific suppression of the immune response to autoantigens to achieve effective treatment of MS by effectively reducing auto-reactive T cell responses through pMHC-coated NPs.
• pMHC-NPs Development for Chronic Inflammatory Disease. Chronic inflammatory diseases are usually treated by systemic administration of immunosuppressive or anti-inflammatory drugs, but the long-term use of these drugs may have additional toxic effects and limited therapeutic efficacy, therefore, there is an urgent need to develop effective treatments that target specific cells/tissues. The induction of anti-inflammatory responses in cells or tissues by administering effective amounts of pMHC-NPs complexes is a promising alternative therapy.
• pMHC-NPs Development for Allergy. Allergy is an IgE antibody-mediated hypersensitivity disorder and is a common disease. While drug-based anti-inflammatory therapy can reduce allergy symptoms, only allergen-specific immunotherapy is the fundamental treatment for the cause. We can provide pMHC-based allergy therapy development services to restore immune homeostasis in allergic individuals through relevant pMHC-coated NPs as a viable alternative to allergy treatment.

Our Highlights

• Superior ability to identify and select candidate pMHCs for specific autoimmune diseases.
• Large number of spontaneous and experimental autoimmune disease models.
• Ensure the rational design and biological activity of key NP and pMHC.

Creative BioMart is dedicated to the research and development of MHC-based nanomedicines to provide satisfactory answers to our customers' autoimmune disease treatment programs. Please do not hesitate to contact us.

References

• Yang Y and Pere S. "Antigen-specific nanomedicines for the treatment of autoimmune disease: target cell types, mechanisms and outcomes." Current Opinion in Biotechnology (2022), 74, 285-292.
• Flemming A. "Nanoparticles engineered for antigen-specific immunotherapy." Nat Rev Immunol (2016), 16, 205.